vs
Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ROGERS CORP is the larger business by last-quarter revenue ($200.5M vs $154.2M, roughly 1.3× BridgeBio Pharma, Inc.). ROGERS CORP runs the higher net margin — 2.2% vs -126.2%, a 128.5% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs 5.2%). ROGERS CORP produced more free cash flow last quarter ($1.1M vs $-56.5M).
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
BBIO vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $200.5M |
| Net Profit | $-194.6M | $4.5M |
| Gross Margin | 94.7% | 32.2% |
| Operating Margin | -90.5% | — |
| Net Margin | -126.2% | 2.2% |
| Revenue YoY | 2521.2% | 5.2% |
| Net Profit YoY | 27.2% | 421.4% |
| EPS (diluted) | $-1.00 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $154.2M | $201.5M | ||
| Q3 25 | $120.7M | $216.0M | ||
| Q2 25 | $110.6M | $202.8M | ||
| Q1 25 | $116.6M | $190.5M | ||
| Q4 24 | — | $192.2M | ||
| Q3 24 | — | $210.3M | ||
| Q2 24 | — | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $-194.6M | $4.6M | ||
| Q3 25 | $-184.9M | $8.6M | ||
| Q2 25 | $-183.8M | $-73.6M | ||
| Q1 25 | $-169.6M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | — | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 94.7% | 31.5% | ||
| Q3 25 | 94.6% | 33.5% | ||
| Q2 25 | 96.7% | 31.6% | ||
| Q1 25 | 97.7% | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | -90.5% | 3.5% | ||
| Q3 25 | -120.3% | 7.3% | ||
| Q2 25 | -121.4% | -33.3% | ||
| Q1 25 | -89.5% | -0.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | -126.2% | 2.3% | ||
| Q3 25 | -153.2% | 4.0% | ||
| Q2 25 | -166.2% | -36.3% | ||
| Q1 25 | -145.4% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | — | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-1.00 | $0.20 | ||
| Q3 25 | $-0.95 | $0.48 | ||
| Q2 25 | $-0.95 | $-4.00 | ||
| Q1 25 | $-0.88 | $-0.08 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | — | $0.58 | ||
| Q2 24 | — | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $570.1M | $195.8M |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $-2.1B | $1.2B |
| Total Assets | $936.0M | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $570.1M | $197.0M | ||
| Q3 25 | $643.0M | $167.8M | ||
| Q2 25 | $756.9M | $157.2M | ||
| Q1 25 | $540.6M | $175.6M | ||
| Q4 24 | — | $159.8M | ||
| Q3 24 | — | $146.4M | ||
| Q2 24 | — | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-2.1B | $1.2B | ||
| Q3 25 | $-1.9B | $1.2B | ||
| Q2 25 | $-1.8B | $1.2B | ||
| Q1 25 | $-1.6B | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $936.0M | $1.4B | ||
| Q3 25 | $998.3M | $1.4B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $881.6M | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-56.4M | $5.8M |
| Free Cash FlowOCF − Capex | $-56.5M | $1.1M |
| FCF MarginFCF / Revenue | -36.6% | 0.5% |
| Capex IntensityCapex / Revenue | 0.0% | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-56.4M | $46.9M | ||
| Q3 25 | $-109.6M | $28.9M | ||
| Q2 25 | $-80.7M | $13.7M | ||
| Q1 25 | $-199.2M | $11.7M | ||
| Q4 24 | — | $33.7M | ||
| Q3 24 | — | $42.4M | ||
| Q2 24 | — | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-56.5M | $42.2M | ||
| Q3 25 | $-110.0M | $21.2M | ||
| Q2 25 | $-81.3M | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | — | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | -36.6% | 20.9% | ||
| Q3 25 | -91.2% | 9.8% | ||
| Q2 25 | -73.5% | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | — | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.0% | 2.3% | ||
| Q3 25 | 0.4% | 3.6% | ||
| Q2 25 | 0.5% | 4.0% | ||
| Q1 25 | 0.0% | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | — | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
